The U.S. Centers for Medicare & Medicaid Services proposed Medicare coverage of approved CAR-T cell therapies that use the patient’s immune system to fight cancer.
Takeda Pharmaceutical Co. Ltd. posted a 27.9 percent rise in operating profit for the October-December 2018 period, supported by strong sales of the company’s drugs for bowel disease and multiple myeloma.
FDA approved Imbruvica combined with Gazyva for adult patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma.
AbbVie Inc.’s blockbuster cancer treatment Imbruvica in combination with chemotherapy agents failed to meet the main goal in a late-stage study of patients with a form of pancreatic cancer.
Germany-based BioNTech extended a three-year-old collaboration with Sanofi as the companies look to co-develop the first cancer immunotherapy candidate for solid tumors.
PwC’s annual R&D spending report showcases companies that stand out in the field of biotechnology.
South San Francisco-based Genentech filed with the State of California, indicating that the Roche company planned to cut 83 jobs.
Johnson and Johnson said a combination therapy containing the company’s blockbuster cancer drug Imbruvica significantly improved survival in blood cancer patients, compared with drugs currently used as the standard of care.
Johnson & Johnson’s blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed.
Nearly 40 percent of lymphoma patients treated with a single infusion of Gilead Sciences Inc.’s Yescarta were still responding to the cell therapy after at least two years of follow-up.